Baidu
map

Lancet Dia & Endo:小心糖代谢异常,它可能会让你面临终生糖尿病

2015-11-11 崔倩 译 MedSci原创

对于CaHD与瓣膜置换手术相关的手术死亡率有所下降。症状和生存的好处是,当CaHD由经验丰富的多学科团队管理时还会产生症状性和生存利益。

有关于葡萄糖代谢受损的终生危险数据是稀缺的,包括糖尿病前期危险性的数据,糖尿病前期进展到糖尿病以及以前未经胰岛素治疗的患者到胰岛素开始治疗的最终进展的风险数据。该研究的目的是评估的葡萄糖损伤的终生危险性,从正常血糖到糖尿病前期、2型糖尿病、最终使用胰岛素。

在这项前瞻性的以人口为基础的队列分析中,研究人员使用的数据来自鹿特丹人口学研究。研究人员通过使用全科医生的记录:出院信件、药房发药的数据、和研究中心(鹿特丹、荷兰)血清空腹血糖测量记录确定诊断事件。正常血糖、糖尿病前期、糖尿病定义在WHO空腹血糖标准的基础上(血糖正常:≤6.0mmol/L;糖尿病前期:> 6.0mmol/L和<7.0mmol/L;以及糖尿病≥7.0mmol/L或使用降糖药物)。研究人员使用调整死亡的竞争风险后的生存分析的修改版本计算终生风险。研究人员还估计了从糖尿病前期到显性糖尿病和不使用胰岛素治疗到使用胰岛素的进展危险性。此外,研究人员还计算了健康的糖代谢的生活年数。

研究人员从鹿特丹研究中调取了10050名参与者的数据。在后续达14.7年的随访中(1997年4月1日和2012年1月1日之间),1148名参与者发展为糖尿病前期,828名患糖尿病,237名开始胰岛素治疗。在45岁时,剩余的终生风险糖尿病前期为48.7%(95%Cl:46.2-51.3),糖尿病为31.3%(29.3-33.3),使用胰岛素为9.1%(7.8-10.3)。在45岁的人群中,从糖尿病前期发展为糖尿病终生风险为74.0%(95%Cl 67.6-80.5),对于在这个年龄有明显的糖尿病并开始胰岛素治疗的人群终生风险为49.1%(38.2-60.0)。随着年龄的增长终生风险衰减,但随着BMI和腰围的增加而增加。平均而言,重度肥胖的人与正常体重的人相比,没有葡萄糖障碍的生活少10年。

糖代谢异常是对人们健康的一个沉重的负担,而该研究结果强调需要更有效的预防战略,应尽快在一个人的生活中尽可能实施。身体较瘦的个体糖尿病前期和糖尿病的实际终身风险也支持了非肥胖个体的风险因素的控制。

原始出处:

Symen Ligthart,Thijs T W van Herpt,Maarten J G Leening,et al.Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes,Lancet Diabetes & Endocrinology,2015.11.10

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1828297, encodeId=47e0182829eb7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 18 13:04:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637204, encodeId=d73f163e20487, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 10 15:04:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360580, encodeId=dc5e136058065, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570808, encodeId=5d6e15e0808c6, content=<a href='/topic/show?id=ace42309edc' target=_blank style='color:#2F92EE;'>#临终#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23097, encryptionId=ace42309edc, topicName=临终)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d35015719835, createdName=bbjsj_1984, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631777, encodeId=ad361631e77b5, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=)]
    2016-03-18 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1828297, encodeId=47e0182829eb7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 18 13:04:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637204, encodeId=d73f163e20487, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 10 15:04:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360580, encodeId=dc5e136058065, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570808, encodeId=5d6e15e0808c6, content=<a href='/topic/show?id=ace42309edc' target=_blank style='color:#2F92EE;'>#临终#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23097, encryptionId=ace42309edc, topicName=临终)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d35015719835, createdName=bbjsj_1984, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631777, encodeId=ad361631e77b5, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1828297, encodeId=47e0182829eb7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 18 13:04:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637204, encodeId=d73f163e20487, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 10 15:04:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360580, encodeId=dc5e136058065, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570808, encodeId=5d6e15e0808c6, content=<a href='/topic/show?id=ace42309edc' target=_blank style='color:#2F92EE;'>#临终#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23097, encryptionId=ace42309edc, topicName=临终)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d35015719835, createdName=bbjsj_1984, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631777, encodeId=ad361631e77b5, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=)]
    2015-11-12 zz70
  4. [GetPortalCommentsPageByObjectIdResponse(id=1828297, encodeId=47e0182829eb7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 18 13:04:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637204, encodeId=d73f163e20487, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 10 15:04:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360580, encodeId=dc5e136058065, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570808, encodeId=5d6e15e0808c6, content=<a href='/topic/show?id=ace42309edc' target=_blank style='color:#2F92EE;'>#临终#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23097, encryptionId=ace42309edc, topicName=临终)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d35015719835, createdName=bbjsj_1984, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631777, encodeId=ad361631e77b5, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=)]
    2015-11-12 bbjsj_1984
  5. [GetPortalCommentsPageByObjectIdResponse(id=1828297, encodeId=47e0182829eb7, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Mar 18 13:04:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637204, encodeId=d73f163e20487, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Oct 10 15:04:00 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360580, encodeId=dc5e136058065, content=<a href='/topic/show?id=16a6e66155b' target=_blank style='color:#2F92EE;'>#糖代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76615, encryptionId=16a6e66155b, topicName=糖代谢)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570808, encodeId=5d6e15e0808c6, content=<a href='/topic/show?id=ace42309edc' target=_blank style='color:#2F92EE;'>#临终#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23097, encryptionId=ace42309edc, topicName=临终)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d35015719835, createdName=bbjsj_1984, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631777, encodeId=ad361631e77b5, content=<a href='/topic/show?id=875e2542699' target=_blank style='color:#2F92EE;'>#代谢异常#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25426, encryptionId=875e2542699, topicName=代谢异常)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06e21824720, createdName=bettycmoon, createdTime=Thu Nov 12 23:04:00 CST 2015, time=2015-11-12, status=1, ipAttribution=)]

相关资讯

Circulation:识别糖代谢异常人群中心血管事件或死亡的新型标志物

背景:血清生物标记物可识别心血管(CV)高危人群的预后。在ORIGIN试验中8494名血糖异常受试者的生物信息库血清样本,检测284个生物标记物识别那些心血管高危人群的预后或死亡。方法:多重分析检测每个受试者提供的1毫升血清样本中心脏代谢的生物标志物。除去无法检测及分析的生物标志物后,分析8401受试者的237的生物标志物。应用Cox回归模型识别生物标志物,这种标志物可独立影响是3种不同的预后:心

胡大一:关爱糖尿病患者——从“心”开始

糖尿病与心血管疾病(CVD)关系密切,充分认识糖代谢异常与心血管病之间的密切关系,对于心血管疾病多重危险因素的综合防治具有重要意义。Framingham研究30余年随访结果证实,与非糖尿病者相比,糖尿病患者的冠心病、卒中、心力衰竭危险增加2~10倍。中美队列随访至1997年的分析结果显示,糖尿病是中国中年人群冠心病和卒中的独立危险因素,仅次于高血压。中国心血管报告2007提示,中国糖尿病患者缺血性

冠心病及其高危患者的血糖筛查和管理

       大量流行病学与临床研究显示,已进展或未进展至冠心病的心血管疾病患者中,糖代谢异常的流行趋势显著,早期进行糖代谢异常筛查并给予合理的干预可能有助于改善患者心血管预后。然而,基于单纯空腹血糖(FPG)检测易造成较高的漏诊率的缺点,如何有效提高冠心病及其高危患者如高血压、高血脂患者的高血糖检出率是目前广大心血管医生面临的首要问题。   &

Baidu
map
Baidu
map
Baidu
map